Immune-checkpoint inhibitors and neurological adverse events
Lancet Neurol
.
2023 Dec;22(12):1093-1094.
doi: 10.1016/S1474-4422(23)00413-1.
Author
Sudhakar Tummala
1
Affiliation
1
Department of Neuro-oncology, MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:
[email protected]
.
PMID:
37977701
DOI:
10.1016/S1474-4422(23)00413-1
No abstract available
Publication types
Comment
MeSH terms
Humans
Immune Checkpoint Inhibitors* / therapeutic use
Neoplasms*
Substances
Immune Checkpoint Inhibitors